Magnetic Haemofiltration is a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. We have the ambition to become a global player, providing hospitals with a new tool to tackle some of mankind’s most serious diseases.

Keep In Touch

A spin-out from University College London, MediSieve is a multi-award-winning biotech startup. The company has raised a total of £4M in equity funding and won grants worth a total of over £4M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. In December 2020 MediSieve secured a £1.6M grant from the UKRI to support pivotal clinical trials, which are due to start in Q2 2022.

Our multidisciplinary team has experience across various fields of science and technology development.

 

MediSieve Receives Approval for First-in-Man Clinical Investigation

MediSieve Receives Approval for First-in-Man Clinical Investigation
May 24, 2022

Radboud University Medical Center will perform the first trial of the Novel Magnetic Haemoflitration System.
MediSieve Receives Industry Recognition

MediSieve Receives Industry Recognition
April 02, 2022

MediSieve, a biotech company that has developed an innovative blood filtration device, receives recognition and approval from the industry.